In NSCLC alone, we observed higher frequencies of CNAs in many actionable genes in TCGA than in GENIE, such as FGFR1 (9% versus 2%, p < 0.0001) and PIK3CA (18% versus 1%, p < 0.0001) for amplification and CDKN2A (13% versus 0%, p < 0.0001), CDKN2B (20% versus 4%, p < 0.0001) for deletions (Fig. 5(a)). This evidence concerns the gene CDKN2B and non-small cell lung carcinoma.